Beneficial effect of a novel nonsteroidal anti-inflammatory agent with basic character and antioxidant properties on experimental colitis in rats
Abstract
SUMMARY
Ulcerative colitis is a chronic disorder of unknown etiology.
Conservative treatment remains empirical, even today.
The aim of this study was to test the efficacy of a novel nonsteroidal
anti-inflammatory agent {5-(2-hydroxy-ethylamino)-
1-cyclohexyl-2-pentanone} (compound A), with basic
character and antioxidant properties on an experimental
model of ulcerative colitis in rats. The effect of this compound
was compared with that of methyl-prednisolone on
the histological abnormalities and serum levels of Tumor
Necrosis Factor alpha (TNF-᩠of experimental colitis produced
by 2,4,6-trinitrobenzenesulfonic acid (TNB). A total
number of 24 rats were used, randomly assigned to one of
four groups of 6 rats each. Group 1: colitis without treatment
(disease control), group 2: normal animals (control),
group 3: induction of experimental colitis treated with methylprednisolone
(5.3 x 10-3 mmol/kg i.v., every day for 7 days)
and group 4: induction of experimental colitis plus administration
of compound A (0.6 mmol/kg i.v., every day for 7
days). The administration of compound A resulted in a statistically
significant reduction (p
Ulcerative colitis is a chronic disorder of unknown etiology.
Conservative treatment remains empirical, even today.
The aim of this study was to test the efficacy of a novel nonsteroidal
anti-inflammatory agent {5-(2-hydroxy-ethylamino)-
1-cyclohexyl-2-pentanone} (compound A), with basic
character and antioxidant properties on an experimental
model of ulcerative colitis in rats. The effect of this compound
was compared with that of methyl-prednisolone on
the histological abnormalities and serum levels of Tumor
Necrosis Factor alpha (TNF-᩠of experimental colitis produced
by 2,4,6-trinitrobenzenesulfonic acid (TNB). A total
number of 24 rats were used, randomly assigned to one of
four groups of 6 rats each. Group 1: colitis without treatment
(disease control), group 2: normal animals (control),
group 3: induction of experimental colitis treated with methylprednisolone
(5.3 x 10-3 mmol/kg i.v., every day for 7 days)
and group 4: induction of experimental colitis plus administration
of compound A (0.6 mmol/kg i.v., every day for 7
days). The administration of compound A resulted in a statistically
significant reduction (p